TY - JOUR T1 - The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide <sup>18</sup>F-AH111585 in Healthy Volunteers JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1664 LP - 1667 DO - 10.2967/jnumed.108.052126 VL - 49 IS - 10 AU - Brian J. McParland AU - Matthew P. Miller AU - Terence J. Spinks AU - Laura M. Kenny AU - Safiye Osman AU - Mandeep K. Khela AU - Eric Aboagye AU - Raoul C. Coombes AU - Ai-Min Hui AU - Pamela S. Cohen Y1 - 2008/10/01 UR - http://jnm.snmjournals.org/content/49/10/1664.abstract N2 - We report the safety, biodistribution, and internal radiation dosimetry of a new PET tracer, 18F-AH111585, a peptide with a high affinity for the αvβ3 integrin receptor involved in angiogenesis. Methods: PET scans of 8 healthy volunteers were acquired at time points up to 4 h after a bolus injection of 18F-AH111585. 18F activity in whole blood and plasma and excreted urine were measured up to 4 h after injection. In vivo 18F activities in up to 12 source regions were determined from quantitative analysis of the images. The cumulated activities subsequently calculated were then used to determine the internal radiation dosimetry, including the effective dose. Results: Injection of 18F-AH111585 was well tolerated in all subjects, with no serious or drug-related adverse events reported. The main route of 18F excretion was renal (37%), and the 3 highest initial uptakes were by liver (15%); combined walls of the small, upper large, and lower large intestines (11%); and kidneys (9%). The 3 highest absorbed doses were received by the urinary bladder wall (124 μGy/MBq), kidneys (102 μGy/MBq), and cardiac wall (59 μGy/MBq). The effective dose was 26 μGy/MBq. Conclusion: 18F-AH111585 is a safe PET tracer with a dosimetry profile comparable to other common 18F PET tracers. ER -